---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-006421"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2026-01-07T23:59:59+00:00"
generated_at: "2026-05-16T11:22:30.523919+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Crinetics prices $350M common stock offering at $45.95/share to fund PALSONIFY launch

## Summary
- Pricing: 7,620,000 shares at $45.95/share; gross proceeds ~$350M.
- Underwriters granted 30-day option to buy up to 1,143,000 additional shares.
- Net proceeds expected ~$330.2M, or ~$379.8M if option exercised.
- Proceeds to fund commercial launch of PALSONIFY, R&D, and general corporate purposes.
- Offering expected to close January 8, 2026.

## SEC filing metadata
- accession: 0001193125-26-006421
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2026-01-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000119312526006421/0001193125-26-006421-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000119312526006421/d22132d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-006421
- JSON: https://secwatch.observer/filing/0001193125-26-006421.json
- Plain text: https://secwatch.observer/filing/0001193125-26-006421.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.